Technical Analysis for NEU - Neuren Pharmaceuticals Ltd
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | -0.56% | |
| Wide Bands | Range Expansion | -0.56% | |
| Down 3 Days in a Row | Weakness | -0.56% |
| Alert | Time |
|---|---|
| Down 2% | about 8 hours ago |
| Reversed from Up | about 9 hours ago |
| 1.5x Volume Pace | about 10 hours ago |
| Up 3% | about 10 hours ago |
| Gap Up Closed | about 10 hours ago |
Get a Trading Sidekick!
Neuren Pharmaceuticals Ltd Description
Neuren Pharmaceuticals Limited (Neuren) is a biopharmaceutical company engaged in developing drugs for neurological disorders. The Company develops therapies for brain injury, neurodevelopmental and neurodegenerative disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. Its products include NNZ-2566 and NNZ-2591. Its lead product, NNZ-2566 (Trofinetide), is in Phase II trial for the treatment of Rett syndrome, Fragile X syndrome, moderate to severe Traumatic Brain Injury (TBI) and Concussion. Trofinetide is an analog of a molecule, which is derived from insulin-like growth factor-1 (IGF-1) and occurs naturally in the brain. Its NNZ-2591 product is in Pre-clinical and Phase I trial for the treatment of other neurological conditions. Its subsidiaries include Hamilton Pharmaceuticals Inc. and Neuren Pharmaceuticals Inc.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Medicine Pharmaceutical Drugs Pharmaceuticals Biopharmaceutical Disorders Psychiatric Diagnosis Psychiatry Neurological Disorders Chronic Condition Chronic Conditions Concussion
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 25.95 |
| 52 Week Low | 12.02 |
| Average Volume | 578,735 |
| 200-Day Moving Average | 17.981 |
| 50-Day Moving Average | 13.856 |
| 20-Day Moving Average | 14.175 |
| 10-Day Moving Average | 15.282 |
| Average True Range | 0.861 |
| RSI (14) | 38.27 |
| ADX | 29.3 |
| +DI | 27.666 |
| -DI | 41.165 |
| Chandelier Exit (Long, 3 ATRs) | 15.356 |
| Chandelier Exit (Short, 3 ATRs) | 14.604 |
| Upper Bollinger Bands | 18.015 |
| Lower Bollinger Band | 10.334 |
| Percent B (%b) | 0.26 |
| BandWidth | 54.187 |
| MACD Line | 0.101 |
| MACD Signal Line | 0.411 |
| MACD Histogram | -0.3097 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 13.485 | ||||
| Resistance 3 (R3) | 13.517 | 13.173 | 13.298 | ||
| Resistance 2 (R2) | 13.173 | 12.887 | 13.158 | 13.235 | |
| Resistance 1 (R1) | 12.767 | 12.710 | 12.595 | 12.735 | 13.172 |
| Pivot Point | 12.423 | 12.423 | 12.338 | 12.408 | 12.423 |
| Support 1 (S1) | 12.017 | 12.137 | 11.845 | 11.985 | 11.548 |
| Support 2 (S2) | 11.673 | 11.960 | 11.658 | 11.485 | |
| Support 3 (S3) | 11.267 | 11.673 | 11.423 | ||
| Support 4 (S4) | 11.235 |
